On Wednesday July 23, 2014, the FDA approved Targiniq ER (Oxycodone/Naloxone), which is indicated in the treatment of pain requiring both around the clock treatment and use of an opioid and which does not respond to other therapies.
Manufactured by Purdue Pharmaceuticals, Targiniq ER is unique in its design. When it is either crushed, injected, or dissolved, Naloxone is released which is an opioid antagonist used in the treatment of opioid overdoses by reversing the euphoric effects of opioids.
Interestingly enough, Targiniq ER was studied in patients with low back pain who did not respond to other therapies and whose condition warranted usage of this medication. Targiniq ER is not indicated for PRN usage and is a first of its kind dosage form, where an abuse deterrent is “built” into the matrix of a pain medication. Purdue Pharmaceuticals is the same maker of the highly popular and widely known medication OxyContin, whose history and controversy may have played a key role in the development of Targiniq ER.
Only time will tell, after post marketing surveillance and follow-up, if this medication will somehow be abused. Targiniq ER will have an REMS (Risk Evaluation and Mitigation Strategy) with it and all patients will receive a medication guide upon dispensing.
Do not be surprised if you see Targiniq ER appearing on your claims payments very soon. More information can be found on the FDA website at:
- E-Facts and Comparisons. Clinical Drug Information, LLC 2014
- Rhodi Lee Tech Times, July 26, 2014. Targiniq ER painkiller pill designed to prevent abuse, gets FDA approval.